MX2018000745A - Metodos para tratar trastornos del desarrollo con gaboxadol. - Google Patents

Metodos para tratar trastornos del desarrollo con gaboxadol.

Info

Publication number
MX2018000745A
MX2018000745A MX2018000745A MX2018000745A MX2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A
Authority
MX
Mexico
Prior art keywords
syndrome
methods
gaboxadol
disorder
developmental disorders
Prior art date
Application number
MX2018000745A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2018000745A publication Critical patent/MX2018000745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan métodos para tratar trastornos del desarrollo tales como síndrome de Angelman, síndrome X frágil, síndrome de temblor/ataxia asociado a X frágil (FXTAS), trastorno de espectro autista, autismo, síndrome de Asperger, trastorno generalizado del desarrollo, trastorno desintegrativo infantil, síndrome de Rett, síndrome de Lanau-Kleffner, síndrome de Prader-Willi, discinesia tardía y/o síndrome de Williams con gaboxadol o una sal farmacéuticamente aceptable de la misma. Los métodos proporcionan composiciones terapéuticas que pueden usarse para mejorar uno o más síntomas del trastorno del desarrollo.
MX2018000745A 2015-07-17 2016-07-14 Metodos para tratar trastornos del desarrollo con gaboxadol. MX2018000745A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (1)

Publication Number Publication Date
MX2018000745A true MX2018000745A (es) 2018-08-15

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000745A MX2018000745A (es) 2015-07-17 2016-07-14 Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2022004734A MX2022004734A (es) 2015-07-17 2018-01-17 Metodos para tratar trastornos del desarrollo con gaboxadol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004734A MX2022004734A (es) 2015-07-17 2018-01-17 Metodos para tratar trastornos del desarrollo con gaboxadol.

Country Status (16)

Country Link
US (8) US20170014393A1 (es)
EP (1) EP3324961A4 (es)
JP (3) JP2018520189A (es)
KR (1) KR20180031721A (es)
CN (2) CN116531370A (es)
AU (2) AU2016295138B2 (es)
BR (1) BR112018000933A2 (es)
CA (1) CA2992734A1 (es)
CL (1) CL2018000142A1 (es)
CO (1) CO2018000375A2 (es)
HK (1) HK1250951A1 (es)
IL (2) IL256912B2 (es)
MX (2) MX2018000745A (es)
PE (2) PE20190338A1 (es)
TW (2) TWI819995B (es)
WO (1) WO2017015049A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3372229T (pt) 2014-06-06 2021-06-17 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a síndrome de angelman
PE20190338A1 (es) 2015-07-17 2019-03-07 Ovid Therapeutics Inc Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
CN112739353A (zh) * 2018-06-14 2021-04-30 奥维德医疗公司 Mir-92a或mir-145在治疗安格曼综合征中的用途
KR20210049855A (ko) * 2018-08-22 2021-05-06 오비드 테라퓨틱스 인크. 위장관 장애들 및 천식의 치료에서 가복사돌의 사용
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
WO2020106976A1 (en) * 2018-11-21 2020-05-28 Certego Therapeutics Combination of gaboxadol and lithium for the treatment of psychiatric disorders
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
AU2020288999A1 (en) * 2019-06-07 2022-02-03 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
CN114173765A (zh) * 2019-07-15 2022-03-11 奥维德医疗公司 用于治疗性治疗的包含加波沙朵的药物制剂
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
KR20070010136A (ko) * 2004-04-02 2007-01-22 하. 룬트벡 아크티에 셀스카브 가복사돌을 이용한 손상된 호흡 기능의 치료
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
JP2010510314A (ja) * 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
EP3108876A1 (en) 2011-10-13 2016-12-28 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
JP2016501876A (ja) * 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
PT3372229T (pt) 2014-06-06 2021-06-17 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a síndrome de angelman
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
PE20190338A1 (es) 2015-07-17 2019-03-07 Ovid Therapeutics Inc Metodos de tratamiento de trastornos del desarrollo con gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP3334427A4 (en) 2015-08-11 2019-02-06 Ovid Therapeutics, Inc. METHODS OF SEDATION AND PARENTERAL COMPOSITION FOR USE IN INTENSIVE CARE
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
US20230071127A1 (en) 2023-03-09
US20190117632A1 (en) 2019-04-25
EP3324961A4 (en) 2019-03-13
AU2016295138B2 (en) 2021-11-04
US20190255027A1 (en) 2019-08-22
IL256912B2 (en) 2024-01-01
US20190321342A1 (en) 2019-10-24
CN108024997A (zh) 2018-05-11
WO2017015049A1 (en) 2017-01-26
AU2021250862B2 (en) 2023-11-09
US11096929B2 (en) 2021-08-24
US20210030727A1 (en) 2021-02-04
EP3324961A1 (en) 2018-05-30
AU2016295138A1 (en) 2018-02-08
CL2018000142A1 (es) 2018-07-13
US20180338960A1 (en) 2018-11-29
TWI819995B (zh) 2023-11-01
IL256912B1 (en) 2023-09-01
IL256912A (en) 2018-03-29
MX2022004734A (es) 2022-05-13
KR20180031721A (ko) 2018-03-28
PE20190338A1 (es) 2019-03-07
US20180098974A1 (en) 2018-04-12
JP2023103375A (ja) 2023-07-26
CO2018000375A2 (es) 2018-04-19
CA2992734A1 (en) 2017-01-26
CN116531370A (zh) 2023-08-04
IL305342A (en) 2023-10-01
HK1250951A1 (zh) 2019-01-18
JP2018520189A (ja) 2018-07-26
AU2021250862A1 (en) 2021-11-04
US20170014393A1 (en) 2017-01-19
TW202325293A (zh) 2023-07-01
TW201707700A (zh) 2017-03-01
JP2021130687A (ja) 2021-09-09
BR112018000933A2 (pt) 2018-09-04
PE20230735A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
MX2022004734A (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
MX2019001937A (es) Métodos de tratamiento de trastornos del desarrollo con biguanidas.
WO2015075557A3 (en) C/ebp alpha short activating rna compositions and methods of use
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
WO2015067715A3 (en) Gip-glp-1 dual agonist compounds and methods
NZ721952A (en) Delayed release compositions of linaclotide
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
WO2015184257A3 (en) Small molecule transcription modulators of bromodomains
MY189912A (en) Substituted xanthines and methods of use thereof
MX2018001324A (es) Forma cristalina de base libre de lorlatinib.
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2015066426A3 (en) Angiopoietin-based interventions for treating cerebral malaria
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP3630150A4 (en) PURIFIED ANTHELMINTIC COMPOSITIONS AND RELATED PROCEDURES
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2016176620A8 (en) Extracellular matrix compositions for the treatment of cancer or immunological diseases
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
MX2019012285A (es) Metodos de tratamiento de encefalopatias del desarrollo.
WO2016094899A3 (en) Treatment of hmgb1-mediated inflammation
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases